Federated Hermes’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.2M Sell
42,663
-29,159
-41% -$12.9M 0.03% 484
2026
Q1
$32.1M Sell
71,822
-5,839
-8% -$2.72M 0.05% 364
2025
Q4
$35.2M Sell
77,661
-108,908
-58% -$46.9M 0.06% 328
2025
Q3
$73.1M Sell
186,569
-7,390
-4% -$3.09M 0.13% 189
2025
Q2
$86.4M Buy
193,959
+23,726
+14% +$10.9M 0.16% 161
2025
Q1
$82.5M Sell
170,233
-18,842
-10% -$8.78M 0.18% 144
2024
Q4
$76.1M Sell
189,075
-2,864
-1% -$1.33M 0.17% 162
2024
Q3
$89.3M Sell
191,939
-19,703
-9% -$9.46M 0.2% 134
2024
Q2
$99.2M Sell
211,642
-273
-0.1% -$118K 0.24% 101
2024
Q1
$88.6M Buy
211,915
+6,554
+3% +$2.77M 0.2% 129
2023
Q4
$83.6M Buy
205,361
+12,542
+7% +$4.63M 0.21% 116
2023
Q3
$67.1M Buy
192,819
+35,371
+22% +$12.4M 0.18% 139
2023
Q2
$55.4M Sell
157,448
-12,211
-7% -$4.11M 0.14% 190
2023
Q1
$53.5M Buy
169,659
+18,637
+12% +$5.59M 0.13% 183
2022
Q4
$43.6M Sell
151,022
-5,368
-3% -$1.64M 0.12% 217
2022
Q3
$45.3M Sell
156,390
-20,001
-11% -$5.75M 0.13% 200
2022
Q2
$49.7M Sell
176,391
-63,757
-27% -$17.1M 0.14% 198
2022
Q1
$62.7M Sell
240,148
-26,936
-10% -$6.39M 0.14% 187
2021
Q4
$58.7M Buy
267,084
+16,440
+7% +$3.2M 0.11% 242
2021
Q3
$45.5M Buy
250,644
+78,580
+46% +$15.3M 0.09% 295
2021
Q2
$34.7M Sell
172,064
-98,665
-36% -$20.6M 0.06% 358
2021
Q1
$58.2M Sell
270,729
-59,586
-18% -$13.1M 0.11% 236
2020
Q4
$78.1M Sell
330,315
-30,941
-9% -$7.1M 0.16% 164
2020
Q3
$98.3M Sell
361,256
-3,279
-0.9% -$905K 0.23% 106
2020
Q2
$106M Sell
364,535
-34,322
-9% -$9.31M 0.26% 86
2020
Q1
$94.9M Sell
398,857
-9,873
-2% -$2.26M 0.28% 77
2019
Q4
$89.5M Buy
408,730
+27,454
+7% +$5.56M 0.2% 116
2019
Q3
$64.6M Buy
381,276
+56,546
+17% +$10M 0.16% 146
2019
Q2
$59.5M Sell
324,730
-3,680
-1% -$643K 0.14% 158
2019
Q1
$60.4M Buy
328,410
+74,720
+29% +$13.8M 0.15% 149
2018
Q4
$42M Sell
253,690
-47,947
-16% -$8.31M 0.11% 194
2018
Q3
$58.1M Sell
301,637
-94,217
-24% -$16.8M 0.14% 175
2018
Q2
$67.3M Buy
395,854
+154,169
+64% +$23.9M 0.2% 104
2018
Q1
$39.4M Buy
241,685
+192,425
+391% +$31.4M 0.11% 156
2017
Q4
$7.38M Sell
49,260
-2,026
-4% -$300K 0.02% 501
2017
Q3
$7.8M Buy
51,286
+772
+2% +$116K 0.02% 451
2017
Q2
$6.51M Sell
50,514
-10,259
-17% -$1.23M 0.02% 505
2017
Q1
$6.64M Sell
60,773
-47,579
-44% -$4.19M 0.02% 507
2016
Q4
$7.98M Buy
108,352
+3,800
+4% +$309K 0.02% 449
2016
Q3
$9.12M Sell
104,552
-25,333
-20% -$2.39M 0.03% 448
2016
Q2
$11.2M Sell
129,885
-78,121
-38% -$6.75M 0.03% 404
2016
Q1
$16.5M Sell
208,006
-445,492
-68% -$40.3M 0.05% 305
2015
Q4
$82.2M Sell
653,498
-32,720
-5% -$3.95M 0.26% 79
2015
Q3
$71.5M Buy
686,218
+640,554
+1,403% +$82.3M 0.23% 80
2015
Q2
$5.64M Buy
45,664
+110
+0.2% +$13.9K 0.02% 569
2015
Q1
$5.37M Buy
45,554
+38,051
+507% +$4.56M 0.02% 589
2014
Q4
$891K Buy
7,503
+2,650
+55% +$298K ﹤0.01% 1217
2014
Q3
$545K Buy
4,853
+4
+0.1% +$381 ﹤0.01% 1330
2014
Q2
$459K Sell
4,849
-3,148
-39% -$221K ﹤0.01% 1374
2014
Q1
$566K Sell
7,997
-130,837
-94% -$10.4M ﹤0.01% 1313
2013
Q4
$10.3M Sell
138,834
-101,648
-42% -$7.08M 0.04% 435
2013
Q3
$18.2M Buy
240,482
+17,102
+8% +$1.36M 0.07% 246
2013
Q2
$17.8M Buy
+223,380
New +$16.5M 0.07% 226

Other funds holding VRTX

Federated Hermes's VRTX Position: Q2 2026 in Review

Federated Hermes reduced its Vertex Pharmaceuticals (VRTX) stake by 41% in Q2 2026, selling an estimated $12.9M and leaving 42,663 shares worth $21.2M. The position accounts for 0.03% of the portfolio, ranked #484.

Federated Hermes first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $106M in Q2 2020. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Federated Hermes held 42,663 shares of Vertex Pharmaceuticals worth $21.2M as of Q2 2026.
  • Federated Hermes sold 29,159 Vertex Pharmaceuticals shares in Q2 2026, an estimated $12.9M.
  • Vertex Pharmaceuticals made up 0.03% of Federated Hermes's portfolio in Q2 2026, its #484 holding.
  • Federated Hermes first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Federated Hermes's Vertex Pharmaceuticals position peaked at $106M in Q2 2020.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.